South & Central America Botulinum Toxin Market Forecast to 2031
South & Central America Botulinum Toxin Market Forecast to 2031 – Regional Analysis – by Product (Botulinum Toxin A and Botulinum Toxin B), Application (Medical and Aesthetic), and End User (Specialty & Dermatology Clinics, Hospitals & Clinics, and Others)
$2,485 – $3,885
- Description
- Toplines
- Reasons for Buying
- Table of Contents
- List of Tables
- LIst of Figures
- List of Companies
- Reviews (0)
Description
Expanding Therapeutic Applications Fuel South & Central America Botulinum Toxin Market
The botulinum toxins type A and B block vesicular acetylcholine released at neuromuscular and neurosecretory junctions, thereby delivering powerful therapeutic outcomes for treating patients requiring neurorehabilitation intervention. As per clinical reports, botulinum toxins have been proven to have therapeutic effects against headache, salivate, and hyperhidrosis, among others. Botulinum treatment can be adopted as an alternative to surgery. It appears to be a promising alternative to sphincterotomy in patients with chronic anal fissures. Patients suffering from a few autonomic disorders such as ptyalism or gustatory sweating, and hypersecretion of glands (a condition that often occurs after patients undergo surgeries involving parotid glands) respond well to botulinum toxins. Despite numerous advancements in the field of assisted reproductive technology, a significant number of patients still suffer from repeated implantation failure. Adequate endometrial growth plays a crucial role in embryo implantation and pregnancy continuation in an assisted reproductive procedure. For several years, botulinum toxins have been widely used in plastic and aesthetic surgeries; it has been revealed that botulinum toxins have a positive influence on the re-epithelialization of human keratinocytes and the angiogenesis of endothelial cells. Clinical results reveal that botulinum toxin administration facilitates the recovery of damaged structure and impaired function of the thin endometrium by increasing cellular proliferation and vessel formation, reducing collagen-accumulated lesions, and ultimately contributing to successful embryo implantation. Thus, the expanding therapeutic applications of botulinum toxins are likely to bring new botulinum toxins market trends in the coming years.
South & Central America Botulinum Toxin Market Overview
The botulinum toxin market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. Market growth in this region is mainly driven by the rising public awareness about cosmetic procedures, the accessibility of technologically advanced user-friendly products, and the increasing demand for aesthetic treatments. In Brazil, minimally invasive and noninvasive cosmetic procedures are being performed for the treatment of a broad range of indications. BOTOX, Xeomin, Dysport, Botulift, and Prosigne are among the botulinum toxin A formulations available in Brazil. The ISAPS report reveals that botulinum toxin-based treatment was the most common non-surgical procedure performed in Brazil in 2021. Nearly 542,520 botulinum toxin procedures, accounting for 49.8% of the total nonsurgical procedures, were performed in the country in the said year. Moreover, the presence of key players positively impacts the growth of the botulinum toxin market in Brazil. In February 2020, Daewoong Pharmaceuticals announced receiving approval from ANVISA for using and selling Nabota, a botulinum toxin product type, in Brazil. Also, Hugel, one of the prominent aesthetics and therapeutics companies, has marketed its botulinum toxin brand in 27 countries, including Brazil.
South & Central America Botulinum Toxin Market Revenue and Forecast to 2031 (US$ Million)
South & Central America Botulinum Toxin Market Segmentation
The South & Central America botulinum toxin market is categorized into product, application, end user, and country.
Based on product, the South & Central America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held a larger share of South & Central America botulinum toxin market share in 2023.
In terms of application, the South & Central America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held a larger share of South & Central America botulinum toxin market in 2023. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.
By end user, the South & Central America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held the largest share of South & Central America botulinum toxin market in 2023.
Based on country, the South & Central America botulinum toxin market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America botulinum toxin market share in 2023.
Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Medytox Inc, and Galderma SA are some of the leading companies operating in the South & Central America botulinum toxin market.
Summary Info
| Industry: | |
|---|---|
| Pricing options: | |
| Geographical coverage: | |
| Year of Publication: |
According to The Research Team’ research, the South & Central America botulinum toxin market was valued at US$ 280.48 million in 2023 and is expected to reach US$ 766.64 million by 2031, registering a CAGR of 13.4% from 2023 to 2031. Rising adoption aesthetic procedure in emerging economies is offering significant and increasing use of botulinum toxin for enhancing facial aesthetics are among the critical factors attributed to drive the South & Central America botulinum toxin market growth.
Healthcare providers in developing economies are focusing on introducing various advanced medical aesthetic technologies into their service portfolios. Health facilities, medical spas, and wellness centers in these countries also offer a comprehensive range of inexpensive but high-quality medical-aesthetic procedures. Patients from developed regions approach emerging countries to undergo various aesthetic procedures. Moreover, people in these countries are willing to spend on cosmetic and rejuvenation procedures to improve aesthetics. Rising disposable income and changing beauty standards have led to an increase in demand for botulinum toxin and similar products in the abovementioned region. Moreover, the botulinum toxin industry is flourishing in India as people seek nonsurgical cosmetic alternatives to invasive procedures. Further, countries in Asia Pacific and Latin America are catching up to the botulinum toxin market in Brazil, Argentina, India, and Thailand usage due to urbanization and increased healthcare spending. Rising healthcare spending in developing economies in Asia Pacific, and South & Central America enables healthcare professionals to adopt advanced technologies for performing cosmetic procedures. For instance, according to the ISAPS, in 2021 the number of non-surgical procedures in Brazil, Argentina, India and Thailand was 542,520; 158,900; 404,016; and 29,840, respectively. Thus, evolving consumer preferences, and growing awareness, developing countries offer significant opportunities for the botulinum toxin market.
On the contrary, side effects of botulinum toxin hamper the growth of South & Central America botulinum toxin market.
Based on product, the South & Central America botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held 98.4% share of South & Central America botulinum toxin market share in 2023, amassing US$ 275.91 million. It is projected to garner US$ 758.04 million by 2031 to register 13.5% CAGR during 2023–2031.
In terms of application, the South & Central America botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held 55.0% share of South & Central America botulinum toxin market in 2023, amassing US$ 154.38 million. It is anticipated to garner US$ 445.60 million by 2031 to expand at 14.2% CAGR during 2023–2031. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.
By end user, the South & Central America botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held 48.2% share of South & Central America botulinum toxin market in 2023, amassing US$ 135.22 million. It is projected to garner US$ 392.99 million by 2031 to expand at 14.3% CAGR from 2023 to 2031.
Based on country, the South & Central America botulinum toxin market is categorized into Brazil, Argentina, and the Rest of South and Central America. Our regional analysis states that Brazil captured 58.0% share of South & Central America botulinum toxin market in 2023. It was assessed at US$ 162.64 million in 2023 and is likely to hit US$ 440.99 million by 2031, registering a CAGR of 13.3% during 2023–2031.
Key players operating in the South & Central America botulinum toxin market are Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Medytox Inc, and Galderma SA , among others.
In August-2021, Merz Therapeutics and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced that they have entered into a strategic license and collaboration agreement to deliver botulinum neurotoxin A (XEOMIN)to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder, interstitial cystitis, and other urology indications.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the South & Central America botulinum toxin market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the South & Central America botulinum toxin market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Botulinum Toxin Market – Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
4.2 Market Restraints
4.2.1 Side Effects of Botulinum Toxin
4.3 Market Opportunities
4.3.1 Rising Adoption of Aesthetic Procedure in Emerging Economies
4.4 Future Trends
4.4.1 Expanding Therapeutic Applications
4.5 Impact of Drivers and Restraints:
5. Botulinum Toxin Market – South & Central America Analysis
5.1 Overview
5.2 Botulinum Toxin Market Revenue (US$ Million), 2021–2031
6. South & Central America Botulinum Toxin Market Analysis – by Product
6.1 Overview
6.2 Botulinum Toxin A
6.2.1 Overview
6.2.2 Botulinum Toxin A: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
6.3 Botulinum Toxin B
6.3.1 Overview
6.3.2 Botulinum Toxin B: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7. South & Central America Botulinum Toxin Market Analysis – by Application
7.1 Overview
7.2 Medical
7.2.1 Overview
7.2.2 Medical: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.2.2.1 South & Central America Botulinum Toxin Market Breakdown, by Medical
7.3 Aesthetic
7.3.1 Overview
7.3.2 Aesthetic: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.3.2.1 South & Central America Botulinum Toxin Market Breakdown, by Aesthetic
8. South & Central America Botulinum Toxin Market Analysis – by End User
8.1 Overview
8.2 Specialty and Dermatology Clinics
8.2.1 Overview
8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Hospitals and Clinics
8.3.1 Overview
8.3.2 Hospitals and Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9. South & Central America Botulinum Toxin Market – Country Analysis
9.1 South & Central America: Botulinum Toxin Market
9.1.1 South & Central America: Botulinum Toxin Market – Revenue and Forecast Analysis – by Country
9.1.1.1 South & Central America: Botulinum Toxin Market – Revenue and Forecast Analysis – by Country
9.1.1.2 Brazil: Botulinum Toxin Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.2.1 Overview
9.1.1.2.2 Brazil: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.2.3 Brazil: Botulinum Toxin Market Breakdown, by Product
9.1.1.2.4 Brazil: Botulinum Toxin Market Breakdown, by Application
9.1.1.2.4.1 Brazil: Botulinum Toxin Market Breakdown, by Medical
9.1.1.2.4.2 Brazil: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.2.5 Brazil: Botulinum Toxin Market Breakdown, by End User
9.1.1.3 Argentina: Botulinum Toxin Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 Argentina: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.3.3 Argentina: Botulinum Toxin Market Breakdown, by Product
9.1.1.3.4 Argentina: Botulinum Toxin Market Breakdown, by Application
9.1.1.3.4.1 Argentina: Botulinum Toxin Market Breakdown, by Medical
9.1.1.3.4.2 Argentina: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.3.5 Argentina: Botulinum Toxin Market Breakdown, by End User
9.1.1.4 Rest of South & Central America: Botulinum Toxin Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.4.1 Overview
9.1.1.4.2 Rest of South & Central America: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.4.3 Rest of South & Central America: Botulinum Toxin Market Breakdown, by Product
9.1.1.4.4 Rest of South & Central America: Botulinum Toxin Market Breakdown, by Application
9.1.1.4.4.1 Rest of South & Central America: Botulinum Toxin Market Breakdown, by Medical
9.1.1.4.4.2 Rest of South & Central America: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.4.5 Rest of South & Central America: Botulinum Toxin Market Breakdown, by End User
10. Company Profiles
10.1 Merz Pharma GmbH & Co KGaA
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 AbbVie Inc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Ipsen SA
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Medytox Inc
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Galderma SA
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
11. Appendix
11.1 About The Research Team
11.2 Glossary of Terms
Table 1. Botulinum Toxin Market Segmentation. 9
Table 2. South & Central America Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 3. South & Central America Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 4. South & Central America: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Country
Table 5. Brazil: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 6. Brazil: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 7. Brazil: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 8. Brazil: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 9. Brazil: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 10. Argentina: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 11. Argentina: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 12. Argentina: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 13. Argentina: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 14. Argentina: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 15. Rest of South & Central America: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 16. Rest of South & Central America: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 17. Rest of South & Central America: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 18. Rest of South & Central America: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 19. Rest of South & Central America: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 20. Glossary of Terms
Figure 1. Botulinum Toxin Market Segmentation, by Country
Figure 2. Botulinum Toxin Market – Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Botulinum Toxin Market Revenue (US$ Million), 2021–2031
Figure 5. Botulinum Toxin Market Share (%) – by Product (2023 and 2031)
Figure 6. Botulinum Toxin A: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. Botulinum Toxin B: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Botulinum Toxin Market Share (%) – by Application (2023 and 2031)
Figure 9. Medical: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Aesthetic: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Botulinum Toxin Market Share (%) – by End User (2023 and 2031)
Figure 12. Specialty and Dermatology Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Hospitals and Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. South & Central America: Botulinum Toxin Market, by Key Country – Revenue (2023) (US$ Million)
Figure 16. South & Central America: Botulinum Toxin Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 17. Brazil: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Argentina: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Rest of South & Central America: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
The List of Companies – South & Central America Botulinum Toxin Market
o Merz Pharma GmbH & Co KGaA
o AbbVie Inc
o Ipsen SA
o Medytox Inc
o Galderma SA
You must be logged in to post a review.
Reviews
There are no reviews yet.